10-(2,2,2-trifluoroethoxy)-19-oxa-1,7,9,11,13,25,32-heptazapentacyclo[23.2.2.23,6.215,18.18,12]tetratriaconta-3(34),4,6(33),8,10,12(32),15(31),16,18(30)-nonaen-2-one | 1287220-06-7

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 大环内酰胺类
• 英文名称: 10-(2,2,2-trifluoroethoxy)-19-oxa-1,7,9,11,13,25,32-heptazapentacyclo[23.2.2.23,6.215,18.18,12]tetratriaconta-3(34),4,6(33),8,10,12(32),15(31),16,18(30)-nonaen-2-one
• CAS: 1287220-06-7
• 化学式: C₂₈H₃₂F₃N₇O₃
• 分子量: 571.602
• InChiKey: CYQPBHLMQKXYFH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  41
• 可旋转键数：
  2
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  105
• 氢给体数：
  2
• 氢受体数：
  12

文献信息

• COMPOUNDS FOR THE TREATMENT OF HEPATITIS C
  申请人：Bristol-Myers Squibb Company

  公开号：EP2488526B1

  公开（公告）日：2013-07-24
• [EN] COMPOUNDS FOR THE TREATMENT OF HEPATITIS C<br/>[FR] COMPOSÉS POUR LE TRAITEMENT DE L'HÉPATITE C
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2011047119A1

  公开（公告）日：2011-04-21

  The disclosure provides compounds of formula (I), including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.